Acumen Pharmaceuticals (ABOS) vs Alpha Cognition (ACOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, gaining 20.4% versus a loss of 16.7%. Alpha Cognition is the larger company by market cap ($178.4 million vs $122.2 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | ACOG |
|---|---|---|
| Share price | $1.69 | $8.19 |
| Market cap | $122.22M | $178.36M |
| 1-day change | +1.20% | -3.08% |
| YTD return | -19.91% | +26.00% |
| 1-year return | -16.75% | +20.44% |
| 5-year return | -88.25% | — |
| EPS (TTM) | $-1.64 | $-1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.22M |
| Net income (latest FY) | $-121.33M | $-20.67M |
| Gross margin | — | 94.10% |
| Operating margin | — | -221.72% |
| Net margin | — | -202.24% |
| 52-week high | $3.60 | $10.14 |
| 52-week low | $1.50 | $4.50 |
| Distance from 52-week high | -53.06% | -19.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +349.70% | +119.78% |
| Average volume | 439.26K | 127.06K |
| Shares outstanding | 72.32M | 21.78M |
| Employees | 60 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACOG has outperformed ABOS by 37.2 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
ABOS vs ACOG FAQ
Which is bigger, Acumen Pharmaceuticals or Alpha Cognition?
Alpha Cognition (ACOG) is larger, with a market capitalization of $178.36M compared with $122.22M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or ACOG?
ACOG returned +20.44% over the past 12 months, compared with -16.75% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Alpha Cognition in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.